<DOC>
	<DOCNO>NCT00004776</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate safety efficacy oral topiramate patient Lennox-Gastaut syndrome .</brief_summary>
	<brief_title>Phase III Randomized , Double-Blind , Placebo-Controlled Study Oral Topiramate Lennox-Gastaut Syndrome</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Following 28-day baseline period , patient randomly assign oral topiramate placebo . The dose study medication titrate first 3 week ; maintenance dose administer next 5 week . Extended topiramate treatment available patient randomize therapy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics LennoxGastaut syndrome Slow spike wave pattern electroencephalogram At least 60 seizure atypical absence drop attack within 1 month Seizure type allow addition : Tonic Tonicclonic Myoclonic Minor motor Absence progressive lesion confirm computerized tomography magnetic resonance imaging No change document physical exam subsequent image No generalized status epilepticus within 3 month comply drug therapy No seizures result progressive disease , e.g . : Active infection Neoplasm Metabolic disorder No anoxic episode require resuscitation within 1 year Prior/Concurrent Therapy 1 2 concurrent maintenance antiepileptic require At least 6 month since corticotropin At least 60 day since acetazolamide zonisamide At least 60 day since investigational drug device No ketogenic diet Patient Characteristics Hematopoietic : No hematological abnormality within 2 year Hepatic : No hepatic disease within 2 year Renal : No nephrolithiasis No renal disease within 2 year Cardiovascular : No clinically significant electrocardiographic abnormality No cardiovascular disease within 2 year Pulmonary : No respiratory disease within 2 year Other : Weight least 25 lb ( 11.5 kg ) No medical disease within 2 year , e.g . : Rheumatic fever Gastrointestinal abnormality Malignancy No psychiatric mood disorder inconsistent LennoxGastaut within 6 month require follow : Electroconvulsive therapy Antidepressants Anxiolytics Antipsychotics Lithium carbonate No history alcohol drug abuse No history poor compliance past antiepileptic therapy Able take medication maintain seizure calendar ( assistance allow ) Adequate parental supervision 1 parent/guardian adequate English fluency English patient 's primary language The following require fertile woman : Negative serumbeta pregnancy test immediately prior entry Normal menstrual flow 3 month prior entry Medically acceptable form contraception study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>Lennox-Gastaut syndrome</keyword>
	<keyword>epilepsy</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>seizure</keyword>
</DOC>